These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 3257143

  • 1. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins.
    Uckun FM, Jaszcz W, Ambrus JL, Fauci AS, Gajl-Peczalska K, Song CW, Wick MR, Myers DE, Waddick K, Ledbetter JA.
    Blood; 1988 Jan; 71(1):13-29. PubMed ID: 3257143
    [Abstract] [Full Text] [Related]

  • 2. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against BCL-1 murine B-cell leukemia.
    Uckun FM, Chelstrom LM, Irvin JD, Finnegan D, Gunther R, Young J, Kuebelbeck V, Myers DE, Houston LL.
    Blood; 1992 May 15; 79(10):2649-61. PubMed ID: 1375109
    [Abstract] [Full Text] [Related]

  • 3. Production of a pokeweed antiviral protein (PAP)-containing immunotoxin, B43-PAP, directed against the CD19 human B lineage lymphoid differentiation antigen in highly purified form for human clinical trials.
    Myers DE, Irvin JD, Smith RS, Kuebelbeck VM, Uckun FM.
    J Immunol Methods; 1991 Feb 15; 136(2):221-37. PubMed ID: 1705571
    [Abstract] [Full Text] [Related]

  • 4. B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells.
    Uckun FM, Fauci AS, Heerema NA, Song CW, Mehta SR, Gajl-Peczalska K, Chandan M, Ambrus JL.
    Blood; 1987 Oct 15; 70(4):1020-34. PubMed ID: 3498517
    [Abstract] [Full Text] [Related]

  • 5. G19.4(alpha CD3) x B43(alpha CD19) monoclonal antibody heteroconjugate triggers CD19 antigen-specific lysis of t(4;11) acute lymphoblastic leukemia cells by activated CD3 antigen-positive cytotoxic T cells.
    Anderson PM, Crist W, Hasz D, Carroll AJ, Myers DE, Uckun FM.
    Blood; 1992 Dec 01; 80(11):2826-34. PubMed ID: 1280479
    [Abstract] [Full Text] [Related]

  • 6. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
    Uckun FM, Haissig S, Ledbetter JA, Fidler P, Myers DE, Kuebelbeck V, Weisdorf D, Gajl-Peczalska K, Kersey JH, Ramsay NK.
    Blood; 1992 Jun 15; 79(12):3369-79. PubMed ID: 1375851
    [Abstract] [Full Text] [Related]

  • 7. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia.
    Uckun FM, Gajl-Peczalska KJ, Kersey JH, Houston LL, Vallera DA.
    J Exp Med; 1986 Feb 01; 163(2):347-68. PubMed ID: 3511171
    [Abstract] [Full Text] [Related]

  • 8. Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
    Uckun FM, Myers DE, Irvin JD, Kuebelbeck VM, Finnegan D, Chelstrom LM, Houston LL.
    Leuk Lymphoma; 1993 Apr 01; 9(6):459-76. PubMed ID: 7687916
    [Abstract] [Full Text] [Related]

  • 9. In vivo efficacy of B43 (anti-CD19)-pokeweed antiviral protein immunotoxin against human pre-B cell acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM, Manivel C, Arthur D, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 May 01; 79(9):2201-14. PubMed ID: 1373967
    [Abstract] [Full Text] [Related]

  • 10. Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells.
    Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA.
    Blood; 1990 Dec 15; 76(12):2449-56. PubMed ID: 1702326
    [Abstract] [Full Text] [Related]

  • 11. Detection and characterization of human high molecular weight B cell growth factor receptors on leukemic B cells in chronic lymphocytic leukemia.
    Uckun FM, Fauci AS, Chandan-Langlie M, Myers DE, Ambrus JL.
    J Clin Invest; 1989 Nov 15; 84(5):1595-608. PubMed ID: 2681271
    [Abstract] [Full Text] [Related]

  • 12. Immunobiologic differences between normal and leukemic human B-cell precursors.
    Uckun FM, Ledbetter JA.
    Proc Natl Acad Sci U S A; 1988 Nov 15; 85(22):8603-7. PubMed ID: 2460871
    [Abstract] [Full Text] [Related]

  • 13. Effective immunochemotherapy of CALLA+C mu+ human pre-B acute lymphoblastic leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19) pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Uckun FM, Chelstrom LM, Finnegan D, Tuel-Ahlgren L, Manivel C, Irvin JD, Myers DE, Gunther R.
    Blood; 1992 Jun 15; 79(12):3116-29. PubMed ID: 1375841
    [Abstract] [Full Text] [Related]

  • 14. Antigen-independent regulation of cytoplasmic calcium in B cells with a 12-kDa B-cell growth factor and anti-CD19.
    Ledbetter JA, Rabinovitch PS, June CH, Song CW, Clark EA, Uckun FM.
    Proc Natl Acad Sci U S A; 1988 Mar 15; 85(6):1897-901. PubMed ID: 2450350
    [Abstract] [Full Text] [Related]

  • 15. CD5 antigen-positive B lymphocytes in human B cell ontogeny during fetal development and after autologous bone marrow transplantation.
    Waddick KG, Uckun FM.
    Exp Hematol; 1993 Jun 15; 21(6):791-8. PubMed ID: 7684704
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 17. Effective immunochemotherapy of human t(4;11) leukemia in mice with severe combined immunodeficiency (SCID) using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin plus cyclophosphamide.
    Jansen B, Kersey JH, Jaszcz WB, Gunther R, Nguyen DP, Chelstrom LM, Tuel-Ahlgren L, Uckun FM.
    Leukemia; 1993 Feb 01; 7(2):290-7. PubMed ID: 7678881
    [Abstract] [Full Text] [Related]

  • 18. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.
    Scheuermann RH, Racila E.
    Leuk Lymphoma; 1995 Aug 01; 18(5-6):385-97. PubMed ID: 8528044
    [Abstract] [Full Text] [Related]

  • 19. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R, Chelstrom LM, Tuel-Ahlgren L, Simon J, Myers DE, Uckun FM.
    Blood; 1995 May 01; 85(9):2537-45. PubMed ID: 7537120
    [Abstract] [Full Text] [Related]

  • 20. Analysis of expression and function of CD40 on normal and leukemic human B cell precursors.
    Law CL, Wörmann B, LeBien TW.
    Leukemia; 1990 Nov 01; 4(11):732-8. PubMed ID: 1700237
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.